Correlation Between Oncopeptides and Senzime AB

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Senzime AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Senzime AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncopeptides AB and Senzime AB, you can compare the effects of market volatilities on Oncopeptides and Senzime AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Senzime AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Senzime AB.

Diversification Opportunities for Oncopeptides and Senzime AB

-0.22
  Correlation Coefficient

Very good diversification

The 3 months correlation between Oncopeptides and Senzime is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Senzime AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Senzime AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Senzime AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Senzime AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Senzime AB go up and down completely randomly.

Pair Corralation between Oncopeptides and Senzime AB

Assuming the 90 days trading horizon Oncopeptides AB is expected to generate 1.6 times more return on investment than Senzime AB. However, Oncopeptides is 1.6 times more volatile than Senzime AB. It trades about 0.02 of its potential returns per unit of risk. Senzime AB is currently generating about -0.04 per unit of risk. If you would invest  153.00  in Oncopeptides AB on December 26, 2024 and sell it today you would lose (2.00) from holding Oncopeptides AB or give up 1.31% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Oncopeptides AB  vs.  Senzime AB

 Performance 
       Timeline  
Oncopeptides AB 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Oncopeptides AB are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Oncopeptides is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.
Senzime AB 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Senzime AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Oncopeptides and Senzime AB Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncopeptides and Senzime AB

The main advantage of trading using opposite Oncopeptides and Senzime AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Senzime AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Senzime AB will offset losses from the drop in Senzime AB's long position.
The idea behind Oncopeptides AB and Senzime AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated